KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis
NASDAQ:KRYS - Nasdaq - US5011471027 - Common Stock - Currency: USD
Overall KRYS gets a fundamental rating of 6 out of 10. We evaluated KRYS against 557 industry peers in the Biotechnology industry. While KRYS has a great health rating, its profitability is only average at the moment. KRYS scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes KRYS very considerable for value investing!
1. Profitability
1.1 Basic Checks
KRYS had positive earnings in the past year.
KRYS had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: KRYS reported negative net income in multiple years.
KRYS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 11.54%, KRYS belongs to the best of the industry, outperforming 94.97% of the companies in the same industry.
KRYS has a better Return On Equity (12.59%) than 94.79% of its industry peers.
Looking at the Return On Invested Capital, with a value of 11.96%, KRYS belongs to the top of the industry, outperforming 96.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.54% | ||
| ROE | 12.59% | ||
| ROIC | 11.96% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 37.18%, KRYS belongs to the top of the industry, outperforming 97.85% of the companies in the same industry.
Looking at the Operating Margin, with a value of 40.05%, KRYS belongs to the top of the industry, outperforming 99.28% of the companies in the same industry.
KRYS's Gross Margin of 93.20% is amongst the best of the industry. KRYS outperforms 94.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.05% | ||
| PM (TTM) | 37.18% | ||
| GM | 93.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KRYS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for KRYS has been increased compared to 1 year ago.
The number of shares outstanding for KRYS has been increased compared to 5 years ago.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
KRYS has an Altman-Z score of 26.82. This indicates that KRYS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 26.82, KRYS belongs to the top of the industry, outperforming 95.33% of the companies in the same industry.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 26.82 |
ROIC/WACC1.33
WACC9.02%
2.3 Liquidity
KRYS has a Current Ratio of 9.65. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
KRYS has a Current ratio of 9.65. This is in the better half of the industry: KRYS outperforms 77.02% of its industry peers.
A Quick Ratio of 9.27 indicates that KRYS has no problem at all paying its short term obligations.
KRYS has a better Quick ratio (9.27) than 75.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.65 | ||
| Quick Ratio | 9.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 358.39% over the past year.
The Revenue has grown by 247.51% in the past year. This is a very strong growth!
EPS 1Y (TTM)358.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3900%
Revenue 1Y (TTM)247.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%94.88%
3.2 Future
The Earnings Per Share is expected to grow by 56.83% on average over the next years. This is a very strong growth
KRYS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.10% yearly.
EPS Next Y104.99%
EPS Next 2Y80.06%
EPS Next 3Y66.52%
EPS Next 5Y56.83%
Revenue Next Year41.56%
Revenue Next 2Y43.84%
Revenue Next 3Y42.19%
Revenue Next 5Y34.1%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 31.84, which means the current valuation is very expensive for KRYS.
KRYS's Price/Earnings ratio is rather cheap when compared to the industry. KRYS is cheaper than 93.90% of the companies in the same industry.
When comparing the Price/Earnings ratio of KRYS to the average of the S&P500 Index (26.35), we can say KRYS is valued slightly more expensively.
KRYS is valuated correctly with a Price/Forward Earnings ratio of 13.66.
Compared to the rest of the industry, the Price/Forward Earnings ratio of KRYS indicates a rather cheap valuation: KRYS is cheaper than 94.43% of the companies listed in the same industry.
KRYS's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.84 | ||
| Fwd PE | 13.66 |
4.2 Price Multiples
KRYS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. KRYS is cheaper than 94.43% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, KRYS is valued cheaper than 93.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.6 | ||
| EV/EBITDA | 20.59 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of KRYS may justify a higher PE ratio.
A more expensive valuation may be justified as KRYS's earnings are expected to grow with 66.52% in the coming years.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y80.06%
EPS Next 3Y66.52%
5. Dividend
5.1 Amount
No dividends for KRYS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
132.46
+0.37 (+0.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.99%
Inst Owner Change-0.8%
Ins Owners12.05%
Ins Owner Change-0.3%
Market Cap3.83B
Analysts84.71
Price Target209.3 (58.01%)
Short Float %11.85%
Short Ratio8.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.89%
Min EPS beat(2)-13.89%
Max EPS beat(2)27.68%
EPS beat(4)1
Avg EPS beat(4)0.66%
Min EPS beat(4)-13.89%
Max EPS beat(4)27.68%
EPS beat(8)2
Avg EPS beat(8)-13.88%
EPS beat(12)4
Avg EPS beat(12)-10.34%
EPS beat(16)7
Avg EPS beat(16)-8.28%
Revenue beat(2)0
Avg Revenue beat(2)-5.71%
Min Revenue beat(2)-10.17%
Max Revenue beat(2)-1.26%
Revenue beat(4)1
Avg Revenue beat(4)-1.72%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)5.47%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.52%
PT rev (3m)-2.95%
EPS NQ rev (1m)-3.5%
EPS NQ rev (3m)-21.37%
EPS NY rev (1m)0%
EPS NY rev (3m)2.12%
Revenue NQ rev (1m)-2.91%
Revenue NQ rev (3m)-10.3%
Revenue NY rev (1m)-3.1%
Revenue NY rev (3m)-10.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.84 | ||
| Fwd PE | 13.66 | ||
| P/S | 11.48 | ||
| P/FCF | 29.6 | ||
| P/OCF | 27.64 | ||
| P/B | 3.89 | ||
| P/tB | 3.89 | ||
| EV/EBITDA | 20.59 |
EPS(TTM)4.16
EY3.14%
EPS(NY)9.69
Fwd EY7.32%
FCF(TTM)4.47
FCFY3.38%
OCF(TTM)4.79
OCFY3.62%
SpS11.54
BVpS34.07
TBVpS34.07
PEG (NY)0.3
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.54% | ||
| ROE | 12.59% | ||
| ROCE | 13.42% | ||
| ROIC | 11.96% | ||
| ROICexc | 31.49% | ||
| ROICexgc | 31.49% | ||
| OM | 40.05% | ||
| PM (TTM) | 37.18% | ||
| GM | 93.2% | ||
| FCFM | 38.78% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 132.67% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 98.59% | ||
| Profit Quality | 104.32% | ||
| Current Ratio | 9.65 | ||
| Quick Ratio | 9.27 | ||
| Altman-Z | 26.82 |
F-Score7
WACC9.02%
ROIC/WACC1.33
Cap/Depr(3y)534.57%
Cap/Depr(5y)974.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)358.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3900%
EPS Next Y104.99%
EPS Next 2Y80.06%
EPS Next 3Y66.52%
EPS Next 5Y56.83%
Revenue 1Y (TTM)247.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%94.88%
Revenue Next Year41.56%
Revenue Next 2Y43.84%
Revenue Next 3Y42.19%
Revenue Next 5Y34.1%
EBIT growth 1Y342.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year214.01%
EBIT Next 3Y79.82%
EBIT Next 5YN/A
FCF growth 1Y184.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y224.51%
OCF growth 3YN/A
OCF growth 5YN/A